NCT06096116: Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- State
- Under way
- Phase
- Phase 3
- People
- 120 planned
- Started
- 21 Aug 2024
- Primary completion
- Mar 2028
- Arms
- Low-dose Atenativ, High-dose Atenativ
- Results
- None posted
- 23 Oct 2023: Trial registered
- 21 Aug 2024: Trial started